论文部分内容阅读
目的:探讨外周血网织红细胞百分比(Ret%)在实体瘤化疗后对骨髓抑制监测的临床意义。方法:利用SYSMEXXE-2100全自动血细胞分析仪在化疗前后不同时间测定患者的中性粒细胞以及Ret%。数据结果采用t检验和卡方检验分析。结果:在接受化疗的实体瘤患者中,Ret%的下降早于中性粒细胞计数下降。其中在化疗后第7天Ret%≤0.3%的群体中发生IV度骨髓抑制概率为71.4%,而在Ret%>0.3%群体中为8.3%,两者之间存在统计学差异(P<0.01)。结论:外周血网织红细胞百分比是实体瘤患者化疗后骨髓抑制预见与监测的有效可靠指标。
Objective: To investigate the clinical significance of peripheral blood reticulocyte percentage (Ret%) in the monitoring of myelosuppression after solid tumor chemotherapy. Methods: SYSMEXXE-2100 automatic hematology analyzer was used to measure neutrophil and Ret% of patients at different time before and after chemotherapy. Data results using t-test and chi-square test analysis. Results: In patients with solid tumors undergoing chemotherapy, the decrease in Ret% was earlier than that in neutrophils. Among them, the IV degree of myelosuppression was 71.4% in the group with Ret% ≤0.3% on the seventh day after chemotherapy, and 8.3% in the Ret%> 0.3% group, there was a significant difference between the two (P <0.01 ). Conclusion: The percentage of reticulocyte in peripheral blood is an effective and reliable index for predicting and monitoring myelosuppression in patients with solid tumors after chemotherapy.